Overview

* EyePoint Q3 2025 net revenue declines to $1.0 mln from $10.5 mln in Q3 2024

* Net loss widens to $59.7 mln in Q3 2025, driven by increased clinical trial costs

* Company raises $172.5 mln in oversubscribed equity financing, extending cash runway into Q4 2027

Outlook

* EyePoint expects cash to fund operations into Q4 2027

* Company anticipates DURAVYU Phase 3 data readout in mid-2026

* First patient dosing for DME trials expected in Q1 2026

Result Drivers

* CLINICAL TRIAL COSTS - Increased costs from DURAVYU Phase 3 trials for wet AMD drove higher operating expenses

* OPERATING EXPENSES - For the third quarter ended September 30, 2025, totaled $63.0 million versus $43.3 million in the prior year period

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $582,000

Product

Sales

Q3 Net -$59.73

Income mln

Q3 Basic -$0.85

EPS

Q3 $62.99

Operatin mln

g

Expenses

Q3 -$62.02

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for EyePoint Pharmaceuticals Inc ( EYPT ) is $29.50, about 58% above its November 4 closing price of $12.39

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)